B+
Bull case
20%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
CAPR
Capricor TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Approval despite the non-binding vote, together with reported clinical benefit and manufacturing readiness, could reopen substantial rare-disease commercial value [#8-K-2026-07-30][#SEC-8K-2026-05-12].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Commercialization depends heavily on deramiocel and remains exposed to execution and partner-economics risk, including the Nippon Shinyaku dispute [#SEC-8K-2026-05-12].
Momentum
4
Value
41
Sentiment
23
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.00 · Bull $11.00 · Bear $1.25Analysis 2026-08-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $33.56
Why
Momentum4 · Δ7d +0.1
Value41 · Δ7d -0.1
Sentiment23 · Δ7d +10.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Commercialization depends heavily on deramiocel and remains exposed to execution and partner-economics risk, including the Nippon Shinyaku dispute [#SEC-8K-2026-05-12].
- • FDA may disagree with the company’s efficacy interpretation after the negative advisory vote, creating CRL, delay, or label risk [#8-K-2026-07-30].
- • The 3-9 effectiveness vote is a material adverse signal.
Catalyst clock
2026-08-15
Post-advisory regulatory overhang
Lead driver: Value · See fundamentals
Momentum
4
8% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-15.6
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
23
45% active weight
Current posture
7d trendImproving
Δ7d
+10.2
Δ21d
+18.0
Why this grade
Composite grade F. Momentum 3.6 / Value 40.6 / Sentiment 23.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-04. Scenario method
B
Base case
35%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
Most likely
B-
Bear case
45%
Probability
Target price
$1.25
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$354.65M
Beta
0.39
Shares Out
58.14M
P/E (TTM) · Derived
-2.7
P/S (TTM)
101.91
P/FCF (TTM) · Derived
-2.49
Rev YoY
-100.0%
EPS YoY
+24.0%
Gross Margin
+84.2%
Op Margin
-778.8%
Net Debt
-$300.18M
Current Ratio
7.35
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data